Loading organizations...

§ Private Profile · Ossining, New York 10562, USA
OrthoAccel Technologies is a technology company.
OrthoAccel Technologies develops medical devices to enhance orthodontic treatment. Its core product, AcceleDent, is an FDA-cleared Class II device employing proprietary SoftPulse Technology. This system delivers gentle micropulses to accelerate bone remodeling, facilitating up to 50% faster tooth movement. AcceleDent integrates with traditional orthodontic appliances, significantly reducing patient treatment duration.
Founded in 2007, OrthoAccel Technologies emerged to offer more efficient orthodontic solutions. Mike Lowe is identified as a founder and early CEO, instrumental to its development. The scientific basis for its micropulse technology, accelerating tooth movement, was significantly advanced by Dr. Jeremy Mao, a professor of orthodontics at Columbia University, offering key foundational insight.
The company serves orthodontic patients seeking quicker treatment outcomes and their managing clinicians. Providing technology that shortens time in orthodontic appliances, OrthoAccel Technologies helps patients achieve dental alignment more rapidly. Its vision focuses on improving the orthodontic patient experience, making treatments more efficient and comfortable, advancing care standards.
OrthoAccel Technologies has raised $66.4M across 9 funding rounds.
OrthoAccel Technologies has raised $66.4M in total across 9 funding rounds.
OrthoAccel Technologies has raised $66.4M across 9 funding rounds. Most recently, it raised $15.0M Series C in January 2017.
OrthoAccel Technologies, Inc. is a medical device company founded in 2007 and headquartered in Bellaire, Texas, specializing in developing, manufacturing, marketing, and selling products for dental care and orthodontic treatment.[1][2][3] Its flagship products include AcceleDent Optima, a device that monitors tooth movement to connect patients and practices, and AcceleDent Aura, which uses SoftPulse Technology to generate gentle micropulses accelerating bone remodeling and tooth movement by up to 50% with 20 minutes of daily use.[1][4] These FDA-cleared Class II devices serve orthodontists and patients seeking faster orthodontic outcomes, solving the problem of lengthy treatment times—often reducing them significantly—while maintaining safety and efficacy.[4] The company has raised $80.9M in funding (latest $20.5M debt round six years ago), holds 29 patents including for malocclusion correction systems, and employs 50-249 people with reported revenues around $7.5M-$17.2M, indicating steady but modest growth in the orthodontic acceleration niche.[2][3][6]
OrthoAccel Technologies was established in 2007 in Houston (later Bellaire), Texas, as a privately held firm focused on innovative orthodontic solutions.[1][2][4][5] While specific founders are not detailed in available records, the company quickly developed AcceleDent, its breakthrough device using SoftPulse Technology for accelerated tooth movement, launching first in Europe and Australia in 2009.[4] Pivotal moments included FDA clearance as a Class II medical device, enabling a U.S. launch in 2012 and Canada in 2013, followed by rapid adoption in over 1,000 practices within 1.5 years and a key U.S. patent in September 2013 for its technology.[4] This early traction solidified its position, with ongoing funding supporting expansion to products like AcceleDent Optima.[2]
OrthoAccel rides the trend of medtech innovation in orthodontics, where digital and vibration-based acceleration addresses growing demand for faster, less invasive dental treatments amid rising adult orthodontic adoption and aesthetic priorities.[4] Timing aligns with post-2010s FDA approvals for Class II devices and global expansion, fueled by market forces like aging populations, cosmetic dentistry booms, and tech-enabled personalization in healthcare.[1][2][4] By influencing over 1,000 practices early on and holding extensive patents, it shapes the ecosystem toward accelerated orthodontics, potentially pressuring traditional braces and aligners while enabling orthodontists to differentiate services.[2][4]
OrthoAccel is poised for growth through product iterations like enhanced monitoring in AcceleDent Optima and leveraging its patent portfolio amid rising tele-dentistry and AI-driven orthodontics trends.[1][2] Future success hinges on new funding post its 2019 debt round, international scaling, and clinical validations proving long-term efficacy, potentially expanding into broader craniofacial applications.[2][4] As medtech converges with consumer health wearables, its influence could evolve from niche accelerator to mainstream orthodontic enabler, tying back to its core mission of dramatically shortening smiles' paths to perfection.[1][4]
OrthoAccel Technologies has raised $66.4M in total across 9 funding rounds.
OrthoAccel Technologies's investors include 8VC, 9Yards Capital, Menlo Ventures, S3 Ventures, Tiger Global Management, Vista Venture Partners, Jim Pallotta, Sundeep Madra, HealthpointCapital, Piper Sandler Merchant Banking, Texas Halo Fund, John C. McCormick.